Oleg Movchan Sells 2,790 Shares of Enfusion, Inc. (NYSE:ENFN) Stock

Enfusion, Inc. (NYSE:ENFN - Get Free Report) CEO Oleg Movchan sold 2,790 shares of the business's stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total transaction of $32,029.20. Following the transaction, the chief executive officer now directly owns 643,299 shares in the company, valued at approximately $7,385,072.52. The trade was a 0.43 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Oleg Movchan also recently made the following trade(s):

• On Thursday, March 6th, Oleg Movchan sold 11,452 shares of Enfusion stock. The shares were sold at an average price of $11.39, for a total transaction of $130,438.28.
• On Tuesday, January 7th, Oleg Movchan sold 2,771 shares of Enfusion stock. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23.

Enfusion Price Performance

ENFN stock traded down $0.06 during trading on Friday, hitting $11.24. 970,369 shares of the stock traded hands, compared to its average volume of 1,164,913. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The firm's 50 day moving average is $10.98 and its two-hundred day moving average is $9.89. The stock has a market cap of $1.44 billion, a price-to-earnings ratio of 280.95, a price-to-earnings-growth ratio of 1.85 and a beta of 0.95.

Enfusion (NYSE:ENFN - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analysts' expectations of $53.98 million. Enfusion had a net margin of 1.70% and a return on equity of 6.67%. As a group, analysts anticipate that Enfusion, Inc. will post 0.06 EPS for the current fiscal year.

Remove Ads

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on ENFN. Stifel Nicolaus upped their target price on shares of Enfusion from $11.00 to $13.00 and gave the stock a "buy" rating in a research report on Wednesday, December 18th. Piper Sandler upped their target price on shares of Enfusion from $10.00 to $11.50 and gave the stock a "neutral" rating in a research report on Monday, December 23rd. Finally, William Blair reaffirmed a "market perform" rating on shares of Enfusion in a research report on Monday, January 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $11.13.

Hedge Funds Weigh In On Enfusion

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Mackenzie Financial Corp lifted its stake in Enfusion by 4.8% during the 4th quarter. Mackenzie Financial Corp now owns 31,271 shares of the company's stock valued at $322,000 after acquiring an additional 1,434 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Enfusion by 43.2% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 33,721 shares of the company's stock valued at $347,000 after acquiring an additional 10,173 shares during the period. Squarepoint Ops LLC lifted its stake in Enfusion by 136.2% during the 4th quarter. Squarepoint Ops LLC now owns 35,633 shares of the company's stock valued at $367,000 after acquiring an additional 20,550 shares during the period. State of Wyoming lifted its stake in Enfusion by 52.7% during the 4th quarter. State of Wyoming now owns 76,814 shares of the company's stock valued at $791,000 after acquiring an additional 26,525 shares during the period. Finally, Silvercrest Asset Management Group LLC bought a new position in Enfusion during the 4th quarter valued at about $4,300,000. Institutional investors own 81.05% of the company's stock.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.